机构:[1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.河北医科大学第四医院外一科临床科室[2]Department of Breast Surgery, Xingtai People's Hospital, Xingtai, Hebei 054000, P.R. China.
Funding was provided by the Natural Science Foundation of
Hebei Province (grant nos. H2020206365 and H2021206071),
the Special Fund for Clinical Research of Wu Jieping
Medical Foundation (grant no. 320.6750.2020‑07‑17) and
the Beijing Xisike Clinical Oncology Research Foundation
(grant no. Y‑SY201901‑0021).
第一作者机构:[1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.[2]Department of Breast Surgery, Xingtai People's Hospital, Xingtai, Hebei 054000, P.R. China.
通讯作者:
通讯机构:[1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.[*1]Breast Center, The Fourth Hospital of Hebei Medical University, 169 Changjiang Avenue, Shijiazhuang, Hebei 050000, P.R. China
推荐引用方式(GB/T 7714):
Yang Lixian,Liu Shuo,Yang Liu,et al.miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin.[J].ONCOLOGY LETTERS.2022,23(5):doi:10.3892/ol.2022.13282.
APA:
Yang Lixian,Liu Shuo,Yang Liu,Xu Bin,Wang Meiqi...&Song Zhenchuan.(2022).miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin..ONCOLOGY LETTERS,23,(5)
MLA:
Yang Lixian,et al."miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin.".ONCOLOGY LETTERS 23..5(2022)